| Molecular Formula | C28H34N4O2 |
| Molar Mass | 458.6 |
| Density | 1.19±0.1 g/cm3(Predicted) |
| Boling Point | 718.7±70.0 °C(Predicted) |
| Solubility | 10 mM in DMSO |
| Appearance | solid |
| Color | Off-white or pale yellow |
| pKa | 2.47±0.40(Predicted) |
| Storage Condition | -20°C |
| Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
| In vitro study | VTX-2337 stimulated the production of TNFα and IL-12 In PBMCs with EC50 of 140 nM and 120 nM, respectively. In monocytes and mDCs, VTX-2337 selectively induced TNFα and IL-12 production by NF-κB activation. VTX-2337 also stimulates IFNγ production in NK cells, increases cytolysin function in myogenic NK cells, and enhances ADCC. |
| In vivo study | In a mouse model of ovarian cancer, TX-2337 enhances the effect of liposomal doxorubicin (PLD). |
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.181 ml | 10.903 ml | 21.806 ml |
| 5 mM | 0.436 ml | 2.181 ml | 4.361 ml |
| 10 mM | 0.218 ml | 1.09 ml | 2.181 ml |
| 5 mM | 0.044 ml | 0.218 ml | 0.436 ml |